{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:36Z","timestamp":1707525096124},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,11]]},"DOI":"10.7759\/cureus.37441","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T16:25:50Z","timestamp":1681230350000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use"],"prefix":"10.7759","author":[{"given":"Curtis S","family":"Pacheco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens WW","year":"2016","unstructured":"Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016, 4:565-72. 10.1016\/j.jaip.2016.04.012","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert C","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al.. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019, 394:1638-50. 10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22944","article-title":"Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps","volume":"12","author":"Hellings PW","year":"2022","unstructured":"Hellings PW, Peters AT, Chaker AM, et al.. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022, 12:958-62. 10.1002\/alr.22944","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1901881","article-title":"Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis","volume":"21","author":"Fokkens W","year":"2021","unstructured":"Fokkens W, Van Der Lans R, Reitsma S. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021, 21:575-85. 10.1080\/14712598.2021.1901881","journal-title":"Expert Opin Biol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-022-01048-9","article-title":"Adverse reactions to biologic medications used in allergy and immunology diseases","volume":"22","author":"Chow TG","year":"2022","unstructured":"Chow TG, Franzblau LE, Khan DA. Adverse reactions to biologic medications used in allergy and immunology diseases. Curr Allergy Asthma Rep. 2022, 22:195-207. 10.1007\/s11882-022-01048-9","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T Helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T Helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood C","year":"2022","unstructured":"Bridgewood C, Wittmann M, Macleod T, et al.. T Helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T Helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022, 142:2660-7. 10.1016\/j.jid.2022.03.013","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.088","article-title":"Delayed onset localized urticarial reactions to dupilumab","volume":"147","author":"Xu J","year":"2021","unstructured":"Xu J, Shih J, Kalangara M. Delayed onset localized urticarial reactions to dupilumab. J Allergy Clin Immunol. 2021, 147:12. 10.1016\/j.jaci.2020.12.088","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.09.022","article-title":"Ulcerative injection-site reaction associated with dupilumab therapy","volume":"6","author":"Phan M","year":"2020","unstructured":"Phan M, Linfante A, Kroger K. Ulcerative injection-site reaction associated with dupilumab therapy. JAAD Case Rep. 2020, 6:1350-2. 10.1016\/j.jdcr.2020.09.022","journal-title":"JAAD Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S195512","article-title":"Dupilumab side effect in a patient with atopic dermatitis: a case report study","volume":"13","author":"Albader SS","year":"2019","unstructured":"Albader SS, Alharbi AA, Alenezi RF, Alsaif FM. Dupilumab side effect in a patient with atopic dermatitis: a case report study. Biologics. 2019, 13:79-82. 10.2147\/BTT.S195512","journal-title":"Biologics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00458-6","article-title":"Facial erythema after the treatment of dupilumab in SLE patient","volume":"16","author":"Jang DH","year":"2020","unstructured":"Jang DH, Lee JI, Bae JY, Jung HJ, Park MY, Ahn J. Facial erythema after the treatment of dupilumab in SLE patient. Allergy Asthma Clin Immunol. 2020, 16:60. 10.1186\/s13223-020-00458-6","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.05.014","article-title":"Erythrodermic presentation of psoriasis in a patient treated with dupilumab","volume":"4","author":"Tracey EH","year":"2018","unstructured":"Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018, 4:708-10. 10.1016\/j.jdcr.2018.05.014","journal-title":"JAAD Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell K","year":"2018","unstructured":"Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018, 4:143-4. 10.1016\/j.jdcr.2017.11.020","journal-title":"JAAD Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro M","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al.. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018, 378:2486-96. 10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a\u00a0meta-analysis of randomized clinical trials","volume":"140","author":"Han Y","year":"2017","unstructured":"Han Y, Chen Y, Liu X, et al.. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a\u00a0meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017, 140:888-891.e6. 10.1016\/j.jaci.2017.04.015","journal-title":"J Allergy Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.852","article-title":"Delayed local reaction at a previous injection site reaction with dupilumab","volume":"9","author":"Sumi T","year":"2021","unstructured":"Sumi T, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H, Chiba H. Delayed local reaction at a previous injection site reaction with dupilumab. Respirol Case Rep. 2021, 9:e0852. 10.1002\/rcr2.852","journal-title":"Respirol Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70150-9","article-title":"Disorders of hyperpigmentation","volume":"18","author":"Pandya AG","year":"2000","unstructured":"Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000, 18:91-98. 10.1016\/S0733-8635(05)70150-9","journal-title":"Dermatol Clin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb H","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020, 50:5-14. 10.1111\/cea.13491","journal-title":"Clin Exp Allergy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603187","article-title":"The roles of inflammation in keloid and hypertrophic scars","volume":"11","author":"Wang ZC","year":"2020","unstructured":"Wang ZC, Zhao WY, Cao Y, et al.. The roles of inflammation in keloid and hypertrophic scars. Front Immunol. 2020, 11:603187. 10.3389\/fimmu.2020.603187","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/142702-delayed-hyperpigmented-injection-site-reactions-due-to-chronic-dupilumab-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:43Z","timestamp":1707508723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/142702-delayed-hyperpigmented-injection-site-reactions-due-to-chronic-dupilumab-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.37441","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}